重新审视哮喘药物治疗:现状与未来方向
当前指南/策略以改善肺功能和生活质量、减少症状和急性发作为目标,推荐根据哮喘症状控制水平和未来急性发作风险进行阶梯式调整治疗。这种阶梯式方法虽实用,但未针对异质性疾病的潜在机制;重症哮喘治疗虽有进展(如LAMA附加治疗、靶向细胞因子治疗),但仍存在未满足需求。需要从「一刀切」转向更精准的哮喘管理,识别「可治疗特征」可能有助于制定更个性化的治疗目标。
要点
- 当前指南推荐根据症状控制和未来急性发作风险进行阶梯式调整治疗。
- 阶梯式方法未充分针对哮喘异质性疾病的潜在机制。
- 识别「可治疗特征」可能实现更个性化的哮喘管理。
核心结论
- 当前阶梯式哮喘治疗虽实用但未充分针对疾病异质性,需转向更精准的管理策略。
研究设计与样本
- 综述性文章,讨论当前哮喘药物治疗策略及未来方向。
主要发现
- 当前指南/策略主要考虑改善肺功能和生活质量、减少症状和急性发作。
- 阶梯式调整治疗依据患者当前哮喘症状总体控制和未来急性发作风险。
- 重症哮喘治疗有进展,如在吸入性糖皮质激素/长效β2受体激动剂基础上加用长效抗胆碱能药物,以及针对关键细胞因子的靶向治疗。
- 尽管有上述策略,重症哮喘人群仍存在未满足需求,推动寻找新靶点和改进治疗/预防性治疗的研究。
关键数值与推荐
- 当前指南/策略建议根据患者当前哮喘症状总体控制和未来急性发作风险进行阶梯式上调或下调治疗。
- 在传统吸入性糖皮质激素/长效β2受体激动剂治疗基础上加用长效抗胆碱能药物可用于重症哮喘。
- 针对关键细胞因子的靶向治疗已被引入重症哮喘治疗。
临床怎么用
- 在等待新疗法的同时,应重新评估当前常规「一刀切」方法,转向更精准的哮喘管理。
- 识别导致个体哮喘患者呼吸道症状的「可治疗特征」可能有助于建立更个性化的治疗目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several current guidelines/strategies outline a treatment approach to asthma, which primarily consider the goals of improving lung function and quality of life and reducing symptoms and exacerbations. They suggest a strategy of stepping up or down treatment, depending on the patient's overall current asthma symptom control and future risk of exacerbation. While this stepwise approach is undeniably practical for daily practice, it does not always address the underlying mechanisms of this heterogeneous disease. In the last decade, there have been attempts to improve the treatment of severe asthma, such as the addition of a long-acting antimuscarinic agent to the traditional inhaled corticosteroid/long-acting β2-agonist treatment and the introduction of therapies targeting key cytokines. However, despite such strategies several unmet needs in this population remain, motivating research to identify novel targets and develop improved therapeutic and/or preventative asthma treatments. Pending the availability of such therapies, it is essential to re-evaluate the current conventional "one-size-fits-all" approach to a more precise asthma management. Although challenging, identifying "treatable traits" that contribute to respiratory symptoms in individual patients with asthma may allow a more pragmatic approach to establish more personalised therapeutic goals.
引用
- Cazzola, Page, Matera, et al. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023. PMID: 37474159. doi:10.1183/13993003.00700-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。